Who Paid My Doc
Dalbir Chhabra
Adolescent Medicine New Hyde Park, NY Medical Doctor
NPI 1942276100 CMS profile 42350
26619 Union Tpke, New Hyde Park, NY 11040
General payments
$343
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Dalbir Chhabra of New Hyde Park, NY is reported in the CMS Open Payments database as having received $343 across 8 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 48th percentile of Adolescent Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $53 | 2 | |
| 2023 | General | $22 | 1 | |
| 2022 | General | $23 | 1 | |
| 2021 | General | $125 | 1 | |
| 2020 | General | $120 | 3 |
Beside peers
- Dalbir Chhabra
- Adolescent Medicine median
- Middle half of Adolescent Medicine
- National median
In program year 2025, general payments to Dalbir Chhabra were reported at $53. Among 113 Adolescent Medicine profiles paid that year, the median was $165 and the middle half received between $61 and $402.
Show as a table
| Year | Dalbir Chhabra | Adolescent Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $151 | $36–$708 | $163 |
| 2020 | $120 | $123 | $24–$337 | $114 |
| 2021 | $125 | $155 | $54–$620 | $132 |
| 2022 | $23 | $158 | $50–$556 | $149 |
| 2023 | $22 | $170 | $52–$612 | $160 |
| 2024 | $0 | $182 | $65–$431 | $164 |
| 2025 | $53 | $165 | $61–$402 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 162 drugsPart D claims
11,221
Drug cost
$811,976
Branded share of claims
20.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 565 | $171,349 | |
| Vumerity Diroximel Fumarate | Brand | 11 | $45,802 | |
| Descovy Emtricitabine/Tenofov Alafenam | Brand | 17 | $39,790 | |
| Januvia Sitagliptin Phosphate | Brand | 135 | $38,268 | |
| Tivicay Dolutegravir Sodium | Brand | 27 | $31,444 | |
| Otezla Apremilast | Brand | 13 | $31,052 | |
| Jardiance Empagliflozin | Brand | 96 | $30,138 | |
| Glatopa Glatiramer Acetate | Brand | 12 | $29,629 | |
| Sevelamer Carbonate | Generic | 68 | $17,358 | |
| Santyl Collagenase Clostridium Hist. | Brand | 42 | $15,940 |
The 10 drugs with the highest cost, of 162 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 7 billing codesPaid by Medicare
$32,080
Medicare patients
95
Services billed
474
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Alzheimer's or dementia | 69% | |
| Depression | 57% | |
| Diabetes | 55% | |
| Ischemic heart disease | 51% | |
| Chronic kidney disease | 38% | |
| Heart failure | 31% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
8 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Adolescent Medicine in New York
Dilip Kachare
Adolescent Medicine · Utica, NY
Alla Bogorodovsky
Adolescent Medicine · Yonkers, NY
Sharwan Bagla
Adolescent Medicine · Kings Park, NY
Suzy Bibawy
Adolescent Medicine · Staten Island, NY
Shirley Tansiongco
Adolescent Medicine · Plainview, NY
Dennis Tansiongco
Adolescent Medicine · Plainview, NY
Related records
Adolescent Medicine in New York
Practitioners in the same specialty and state, ranked by reported value.
All Adolescent Medicine
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.